Eghon Guzman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6127/publications.pdf

Version: 2024-02-01

1937457 1719901 13 57 4 7 citations h-index g-index papers 13 13 13 54 citing authors docs citations times ranked all docs

#	Article	IF	CITATIONS
1	Effect of FOLFOX on minimal residual disease in Stage III colon cancer and risk of relapse. Ecancermedicalscience, 2019, 13, 935.	0.6	13
2	Subtypes of minimal residual disease, association with Gleason score, risk and time to biochemical failure in pT2 prostate cancer treated with radical prostatectomy. Ecancermedicalscience, 2019, 13, 934.	0.6	12
3	Minimal Residual Disease Defines the Risk and Time to Biochemical Failure in Patients with Pt2 and Pt3a Prostate Cancer Treated With Radical Prostatectomy: An Observational Prospective Study. Urology Journal, 2020, 17, 262-270.	0.3	6
4	The association of the neutrophil–lymphocyte ratio with the presence of minimal residual disease and outcome in patients with Stage II colon cancer treated with surgery alone. Colorectal Disease, 2021, 23, 805-813.	0.7	5
5	Subtypes of minimal residual disease and outcome for stage II colon cancer treated by surgery alone. Ecancermedicalscience, 2020, 14, 1119.	0.6	5
6	Transient acquired factor XII deficiency associated with moderately severe Covid-19 pneumonia. Hematology, Transfusion and Cell Therapy, 2021, 43, 515-517.	0.1	4
7	The expression of matrix-metalloproteinase-2 in bone marrow micro-metastasis is associated with the presence of circulating prostate cells and a worse prognosis in men treated with radical prostatectomy for prostate cancer. Turkish Journal of Urology, 2020, 46, 186-195.	1.3	4
8	Immune Dysfunction as Measured by the Systemic Immune-Inflammation Index is Associated with the Sub-Type of Minimal Residual Disease and Outcome in Stage II Colon Cancer Treated with Surgery alone. Asian Pacific Journal of Cancer Prevention, 2021, 22, 2391-2397.	0.5	2
9	Subtypes of minimal residual disease and outcome for stage II colon cancer treated by surgery alone. Ecancermedicalscience, 2020, 14, 1119.	0.6	2
10	The Epstein criteria predict for organ-confined prostate cancer but not for minimal residual disease and outcome after radical prostatectomy. Turkish Journal of Urology, 2020, 46, 360-366.	1.3	2
11	Management of mild congenital deficiency of Factor XI with a Factor XI inhibitor in pregnancy: A clinical case. Hematology, Transfusion and Cell Therapy, 2021, , .	0.1	1
12	The CAPRA-S score versus subtypes of minimal residual disease to predict biochemical failure after radical prostatectomy. Ecancermedicalscience, 2020, 14, 1063.	0.6	1
13	The Epstein criteria predict for organ-confined prostate cancer but not for minimal residual disease and outcome after radical prostatectomy. Turkish Journal of Urology, 2020, 46, 360-366.	1.3	0